- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01019434
Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Radiation Therapy and Concurrent Plus Adjuvant Temsirolimus (CCI-779) Versus Chemo-Irradiation With Temozolomide in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Gene Promoter - A Randomized Multicenter, Open-Label, Phase II Study.
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with temsirolimus or temozolomide in treating patients with glioblastoma.
PURPOSE: This randomized phase II trial is studying giving radiation therapy together with temsirolimus to see how well it works compared with giving radiation therapy together with temozolomide in treating patients with newly diagnosed glioblastoma.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Document the activity profile of temsirolimus by the evaluation of overall survival at 1 year in patients with newly diagnosed glioblastoma multiforme, without methylation of the MGMT gene promoter, treated with temsirolimus before and concomitantly with radiotherapy, followed by temsirolimus maintenance therapy.
Secondary
- Investigate safety and tolerability of this therapy regimen in these patients.
- Assess progression-free survival and overall survival of these patients.
- Assess biomarkers in the tumor tissue relevant to temsirolimus and disease state, and their correlation to clinical outcome in these patients.
OUTLINE: This is a multicenter study. Patients are stratified according to institution, age in years (< 50 vs ≥ 50), Karnofsky performance status (PS) (< 80% vs ≥ 80%) OR ECOG PS (0 or 1 vs 2), and corticosteroid use (yes vs no). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Within 7 weeks after surgery or open biopsy, patients undergo radiotherapy 5 days a week for 6 weeks and receive oral temozolomide concurrently once daily for 6 weeks. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients receive adjuvant oral temozolomide once daily on days 1-5. Treatment with adjuvant temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression and unacceptable toxicity.
- Arm II: Within 7 weeks after surgery or open biopsy, patients undergo radiotherapy 5 days a week for 6 weeks. Patients also receive temsirolimus IV over 30-60 minutes once weekly beginning 7 days before initiation of radiotherapy. After completion of chemoradiotherapy, patients receive maintenance temsirolimus IV once weekly in the absence of disease progression and unacceptable toxicity.
Frozen tumor biopsies or paraffin-embedded tumor material obtained from surgery or open biopsy and blood samples are collected for analysis of molecular markers, determination of the methylation status of the MGMT gene promoter (before randomization and at a later time), and other studies.
After completion of study therapy, patients are followed every 3 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium
- UZ Leuven
-
-
-
-
-
Nantes-Saint Herblain, France, 44805
- Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau
-
Paris, France, FR 75651
- Chu Pitie-Salpetriere AP-HP
-
-
-
-
-
Freiburg, Germany, DE 79106
- Universitaetsklinikum Freiburg
-
Heidelberg, Germany, D-69120
- Universitätsklinikum Heidelberg
-
-
-
-
-
Bologna, Italy, I-40139
- Ospedale Bellaria
-
-
-
-
-
Den Haag, Netherlands, NL 2501
- Medisch Centrum Haaglanden - Westeinde
-
Rotterdam, Netherlands, NL 3008
- Erasmus MC - Daniel den Hoed Cancer Center
-
-
-
-
-
Badalona, Spain, ES 08916
- Ico Badalona - Hospital Germans Trias I Pujol
-
-
-
-
-
Bellinzona, Switzerland
- Ospedale Regionale Bellinzona e Valli
-
Zurich, Switzerland, CH-8091
- Universitaetsspital Zuerich
-
-
-
-
-
Edinburgh, United Kingdom
- Western General Hospital
-
-
Wirral
-
Bebington, Wirral, United Kingdom
- Clatterbridge Cancer Centre NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed (by open brain biopsy or from a neurosurgical resection of the tumor) supratentorial glioblastoma multiforme (GBM)
- WHO grade IV disease
- Newly diagnosed disease
- Must provide demonstration of an unmethylated MGMT-promoter
- At least 2 weeks and no more than 6 weeks since surgery or open biopsy
- Tumor tissue specimens (paraffin-embedded and/or frozen) from the GBM surgery or open biopsy must be available for central pathology review, MGMT status determination, and exploratory analysis of PI3-K/Akt/mTOR targets (P70S6K)
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy ≥ 12 weeks
- WBC ≥ 3.0 x 10^9/L
- Absolute neutrophil count ≥ 1.5 x10^9/L
- Platelet count ≥ 75.0 x 10^9/L
- Hemoglobin ≥ 10.0 g/dL
- Bilirubin ≤ 1.5 times the upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2.5 x ULN
- AST and/or ALT ≤ 2.5 x ULN
- Serum creatinine < 1.5 x ULN
- PT and PTT normal
- Negative pregnancy test
- Not pregnant or nursing
- Fertile patients must use highly effective contraception
- No ischemic heart disease in the past 6 months
- 12-lead ECG normal
- No history of stroke
- No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer (with no subsequent evidence of recurrence)
No serious concurrent systemic disorder including any of the following that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol:
- Active infection
- HIV infection
- Cardiac disease
- QTc prolongation > 450/470 msec (males/females)
- No patients with a congenital long-QT-syndrome in their own or family medical history, unless eligible at the investigator's discretion
- No known hypersensitivity to the study treatment
- No known hypersensitivity to antihistamines or other medical reason that prohibits the intake of antihistamines
- No current alcohol dependence or drug abuse
- No legal incapacity or limited legal capacity
- Able to undergo a gadolinium-enhanced MRI of the brain
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- At least 4 weeks since prior and no concurrent investigational agent
- No prior stereotactic biopsy
- At least 30 days since prior drug therapy that has not received regulatory approval for any indication
- No chemotherapy within the past 5 years
- No prior chemotherapy for a brain tumor
- No prior radiotherapy to the head
- No other concurrent anticancer therapy
- No concurrent anticoagulation therapy except low-dose prophylactic low molecular weight heparin
- Concurrent steroid therapy allowed provided patient is on a stable or decreasing dose for ≥ 1 week
- At least 14 days since prior and no concurrent enzyme-inducing anticonvulsants (e.g., carbamazepine, phenobarbital, and phenytoin)
- No concurrent strong inducers or inhibitors of CYP3A4
- No concurrent planned surgery for other diseases (e.g., dental extraction)
- No placement of Gliadel® wafer during prior surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Temozolomide
TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
|
TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
|
EXPERIMENTAL: Temsirolimus
CCI-779 will be given i.v.
once every week at 25 mg.
Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist.
A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
|
CCI-779 will be given i.v.
once every week at 25 mg.
Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist.
A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival at 1 year
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentages of worst Adverse Events or Laboratory Event grades as measured by CTCAEs Version 4.0 criteria
Time Frame: end of trial
|
end of trial
|
Progression-free survival (PFS) probability at 6 months and at 12 months, and overall survival (OS) probability at 2 years
Time Frame: end of trial
|
end of trial
|
Correlation between biomarkers relevant to temsirolimus and PFS and OS
Time Frame: end of trial
|
end of trial
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Gianfranco Pesce, MD, Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Nervous System Neoplasms
- Central Nervous System Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Temozolomide
- Sirolimus
Other Study ID Numbers
- EORTC-26082-22081
- EORTC-26082
- EORTC-22081
- EU-20987
- 2008-003003-31 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain and Central Nervous System Tumors
-
Children's Hospital Los AngelesUnknownBrain and Central Nervous System TumorsUnited States, Canada, Australia, Switzerland, New Zealand
-
Emory UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Abramson Cancer Center of the University of PennsylvaniaNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
St. Jude Children's Research HospitalCompletedBrain Tumors | Central Nervous System TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain Tumors | Central Nervous System TumorsUnited States, Australia, Canada
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)CompletedVNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain TumorsBrain and Central Nervous System TumorsUnited States
-
New Approaches to Brain Tumor Therapy ConsortiumNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
Clinical Trials on temozolomide
-
Guangzhou Medical UniversityUnknownSmall Cell Lung Cancer | Metastatic CarcinomaChina
-
University of SouthamptonBristol-Myers SquibbRecruitingCancer of Esophagus | Adenocarcinoma - GEJUnited Kingdom
-
Novartis PharmaceuticalsCompletedGlioblastomaAustralia, Spain, Canada, United States
-
Activartis BiotechCompleted
-
Bradmer Pharmaceuticals Inc.Terminated
-
Peking Union Medical College HospitalBeijing Tiantan Hospital; Tianjin Medical University General HospitalUnknownMalignant GliomasChina
-
Yunpeng LiuUnknownExtensive Stage Small Cell Lung CancerChina
-
Yong-Kil HongNational Cancer Center, Korea; Samsung Medical Center; Seoul St. Mary's Hospital and other collaboratorsCompletedGlioblastomaKorea, Republic of
-
Medical University of South CarolinaTerminatedGlioma | Astrocytoma | Brain Tumor | Glioblastoma MultiformeUnited States
-
Haukeland University HospitalUniversity of Oslo; Oslo University Hospital; University Hospital of North Norway and other collaboratorsRecruiting